BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Novo Nordisk insulin analogue gets Japanese nod

January 2, 2013 | News | By BioSpectrum Bureau



Singapore:Ã?Â Novo Nordisk announced that theÃ?Â Japanese Ministry of Health, Labour and Welfare has approved RyzodegÃ?Â (insulinÃ?Â degludec/insulin aspart) for the treatment of diabetes.

In Japan, Ryzodeg will be available in FlexTouch, Novo Nordisk's latest prefilled insulin pen, which has an easy auto-injector mechanism, and in Penfill for Novo Nordisk's durable insulin pens.

RyzodegÃ?Â is a soluble formulation of TresibaÃ?Â (insulin degludec), a once-daily new generation basal insulin analogue with an ultra-long duration of action, and NovoRapidÃ?Â (insulin aspart, which in the US is marketed under the brand name NovoLog).

RyzodegÃ?Â can be administered once-or-twice daily with the main meals. In global 'treat-to-target' studies supporting the new drug application, where RyzodegÃ?Â was compared to NovoMix, the former demonstrated a significantly lower risk of nocturnal hypoglycaemia while successfully achieving equivalent reductions in HbA1c.

"We are excited about the approval of Ryzodeg", said Mr Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "The unique properties of RyzodegÃ?Â provide the potential to improve treatment for people with diabetes in Japan".